tetano
Editor, Senior Moderator
Biotechnol Prog. 2019 May 3:e2831. doi: 10.1002/btpr.2831. [Epub ahead of print]
[h=1]Development of an alternating tangential flow (ATF) perfusion-based transient gene expression (TGE) bioprocess for universal influenza vaccine.[/h] Hong J[SUP]1[/SUP], Demirji J[SUP]1[/SUP], Blackstock D[SUP]1[/SUP], Lee J[SUP]1[/SUP], Dinh T[SUP]1[/SUP], Goh A[SUP]1[/SUP], Arnold F[SUP]1[/SUP], Horwitz J[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] An alternating tangential flow (ATF) perfusion-based transient gene expression (TGE) bioprocess has been developed using human embryonic kidney (HEK) 293 cells to produce H1-ss-np, a promising candidate for a universal influenza vaccine. Two major adjustments were taken to improve the process: 1) eliminate the interference of microbubbles during gene transfection; and 2) utilize an ATF perfusion system for a prolonged culture period. As a result, a closed-operation 9-days ATF perfusion-based TGE bioprocess was developed. The TGE bioprocess showed continuous cell growth with high cell viability and prolonged cellular productivity that achieved recombinant product level of ~270 mg/l which was more than 2 times that of 4-days base-line TGE bioprocess. In addition, the consumables cost per milligram for ATF perfusion-based TGE bioprocess was ~70 % lower than that of the base-line TGE bioprocess suggesting high cost savings potential in vaccine manufacturing. Based on the lower contamination risk, higher productivity, and cost efficiency, the ATF perfusion-based TGE bioprocess can likely provide potential benefits to many future applications in vaccine and drug manufacturing. This article is protected by copyright. All rights reserved.
? 2019 American Institute of Chemical Engineers.
[h=4]KEYWORDS:[/h] alternating tangential flow (ATF); mammalian cell culture; perfusion bioreactor; transient gene expression (TGE)
PMID: 31050215 DOI: 10.1002/btpr.2831
[h=1]Development of an alternating tangential flow (ATF) perfusion-based transient gene expression (TGE) bioprocess for universal influenza vaccine.[/h] Hong J[SUP]1[/SUP], Demirji J[SUP]1[/SUP], Blackstock D[SUP]1[/SUP], Lee J[SUP]1[/SUP], Dinh T[SUP]1[/SUP], Goh A[SUP]1[/SUP], Arnold F[SUP]1[/SUP], Horwitz J[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] An alternating tangential flow (ATF) perfusion-based transient gene expression (TGE) bioprocess has been developed using human embryonic kidney (HEK) 293 cells to produce H1-ss-np, a promising candidate for a universal influenza vaccine. Two major adjustments were taken to improve the process: 1) eliminate the interference of microbubbles during gene transfection; and 2) utilize an ATF perfusion system for a prolonged culture period. As a result, a closed-operation 9-days ATF perfusion-based TGE bioprocess was developed. The TGE bioprocess showed continuous cell growth with high cell viability and prolonged cellular productivity that achieved recombinant product level of ~270 mg/l which was more than 2 times that of 4-days base-line TGE bioprocess. In addition, the consumables cost per milligram for ATF perfusion-based TGE bioprocess was ~70 % lower than that of the base-line TGE bioprocess suggesting high cost savings potential in vaccine manufacturing. Based on the lower contamination risk, higher productivity, and cost efficiency, the ATF perfusion-based TGE bioprocess can likely provide potential benefits to many future applications in vaccine and drug manufacturing. This article is protected by copyright. All rights reserved.
? 2019 American Institute of Chemical Engineers.
[h=4]KEYWORDS:[/h] alternating tangential flow (ATF); mammalian cell culture; perfusion bioreactor; transient gene expression (TGE)
PMID: 31050215 DOI: 10.1002/btpr.2831